STAT6-dependent differentiation and production of IL-5 and IL-13 in murine NK2 cells.
NK cells differentiate into either NK1 or NK2 cells that produce IFN-gamma or IL-5 and IL-13, respectively. Little is known, however, about the molecular mechanisms that control NK1 and NK2 cell differentiation. To address these questions, we established an in vitro mouse NK1/NK2 cell differentiation culture system. For NK1/NK2 cell differentiation, initial stimulation with PMA and ionomycin was required. The in vitro differentiated NK2 cells produced IL-5 and IL-13, but the levels were 20 times lower than those of Th2 or T cytotoxic (Tc)2 cells. No detectable IL-4 was produced. Freshly prepared NK cells express IL-2Rbeta, IL-2RgammaC, and IL-4Ralpha. After stimulation with PMA and ionomycin, NK cells expressed IL-2Ralpha. NK1 cells displayed higher cytotoxic activity against Yac-1 target cells. The levels of GATA3 protein in developing NK2 cells were approximately one-sixth of those in Th2 cells. Both NK1 and NK2 cells expressed large amounts of repressor of GATA, the levels of which were equivalent to CD8 Tc1 and Tc2 cells and significantly higher than those in Th2 cells. The levels of histone hyperacetylation of the IL-4 and IL-13 gene loci in NK2 cells were very low and equivalent to those in naive CD4 T cells. The production of IL-5 and IL-13 in NK2 cells was found to be STAT6 dependent. Thus, similar to Th2 cells, NK2 cell development is dependent on STAT6, and the low level expression of GATA3 and the high level expression of repressor of GATA may influence the unique type 2 cytokine production profiles of NK2 cells.
Department of Immunology, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Japan.
Takuo
T
Katsumoto
Motoko
M
Kimura
Masakatsu
M
Yamashita
Hiroyuki
H
Hosokawa
Kahoko
K
Hashimoto
Akihiro
A
Hasegawa
Miyuki
M
Omori
Takeshi
T
Miyamoto
Masaru
M
Taniguchi
Toshinori
T
Nakayama
D000107:Acetylation; D000818:Animals; D002454:Cell Differentiation; D004268:DNA-Binding Proteins / Q000032:analysis; D050981:Erythroid-Specific DNA-Binding Factors; D050989:GATA2 Transcription Factor; D050990:GATA3 Transcription Factor; D007371:Interferon-gamma / Q000096:biosynthesis; D018793:Interleukin-13 / Q000096:biosynthesis*; D007376:Interleukin-2 / Q000494:pharmacology; D015848:Interleukin-5 / Q000096:biosynthesis*; D007694:Killer Cells, Natural / Q000166:cytology* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D015375:Receptors, Interleukin-2 / Q000032:analysis; D019948:Receptors, Interleukin-4 / Q000032:analysis; D050800:STAT6 Transcription Factor; D015534:Trans-Activators / Q000032:analysis / Q000502:physiology*; D014157:Transcription Factors / Q000032:analysis
D004268:DNA-Binding Proteins; D050981:Erythroid-Specific DNA-Binding Factors; D050989:GATA2 Transcription Factor; D050990:GATA3 Transcription Factor; C494712:Gata2 protein, mouse; C494748:Gata3 protein, mouse; D018793:Interleukin-13; D007376:Interleukin-2; D015848:Interleukin-5; D015375:Receptors, Interleukin-2; D019948:Receptors, Interleukin-4; D050800:STAT6 Transcription Factor; C494100:Stat6 protein, mouse; D015534:Trans-Activators; D014157:Transcription Factors; D007371:Interferon-gamma